Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies.  

Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate multi-modal tumour models. 

Using Concr’s cloud native platform – FarrSight® – researchers can computationally simulate clinical trials, make advanced predictions about biomarkers, and perform standard bioinformatics analyses directly. 

Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Deep Science Ventures and SyndicateRoom.

Illumina

Accelerate@Babraham

Avonmore Developments

KQ Labs

R42 Group

University of Cambridge Enterprise

Deep Science Ventures

Cambridge Angels group

Concr

📣 Exciting news! We’ve been named one of Hello Tomorrow's Deep Tech Pioneers! 

Come and meet us at the Hello Tomorrow Global Summit next spring in Paris, alongside industry leaders, investors, researchers and experts in the deep tech ecosystem from all over the world.

More info here 👉  https://bit.ly/ht-24

A special thanks to Loukik Arora, Ph.D. for the encouragement to apply 🙏 

 #DeepTechPioneer #HelloTomorrow #innovation #FromCosmologytoOncology

Looking forward to connect with old and new colleagues tomorrow at this exciting annual event, brought together by Cancer Research Horizons.

Get in touch with our CBO Irina Babina if you're attending and would like to learn more about how we predict patient response and outcomes to increase drug success.

https://lnkd.in/ewggAfzk

📍 Royal Society of Medicine, London
🕘 09:00 - 17:00

#techbio #innovation #precisiononcology #biomarkers #ai #machinelearning #data 

It’s just around the corner!

Concr is presenting at #BIOEurope next week, and attendees can now watch our presentation on demand, and throughout the conference.

Whether you’re a drug developer looking to de-risk development and increase value of your asset; or a Series A investor looking for a techbio opportunity, get in touch with our CBO Irina Babina for a 1:1 meeting now. 

Register to watch our presentation: https://bit.ly/49gqwNn

#biomarkers #precisionmedicine #techbio #drugdevelopment #investment #seriesA #lifesciences #FromCosmologytoOncology

Provider of B2B contacts and company information

Concris

Developing biomarker technology for use in oncology

Techbio Startup

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Their unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding the most accurate multi-modal tumor models.

Concr Pty Ltd

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom	Feb 15, 2024 10:24 PM	46312e3e
company dossier	dataroom	Feb 15, 2024 10:24 PM	e2faee13
network	dataroom
network mapping	dataroom
transactions dossier	dataroom	Feb 15, 2024 10:24 PM	f0c24cad
network onboarding	dataroom
news impact assignment basic	general	Feb 15, 2024 10:24 PM	c8daf4ed
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general	Feb 15, 2024 10:24 PM	660f5173
news impact assignment advanced	general
signals	general	Feb 15, 2024 10:24 PM	62308080
news processing advanced	general
peers	general	Feb 15, 2024 10:24 PM	1a006b94
news basic	general	Feb 15, 2024 10:24 PM	b80307c0
events	markdown	Feb 15, 2024 10:24 PM	9ac184d0
bundesanzeiger	filings	Feb 15, 2024 10:24 PM	6ffb74da
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers	Feb 15, 2024 10:24 PM	7cca75c7

CO:CONCR

Concr Pty Ltd